ImmunoGen, Inc.·4

Jun 17, 4:12 PM ET

Wallace Richard John 4

4 · ImmunoGen, Inc. · Filed Jun 17, 2022

Insider Transaction Report

Form 4
Period: 2022-06-15
Transactions
  • Award

    Deferred Share Unit

    2022-06-15+15,000102,326 total
    Exercise: $0.00Common Stock (15,000 underlying)
  • Award

    Stock Option (right to buy)

    2022-06-15$3.37/sh+44,000$148,28044,000 total
    Exercise: $3.37Exp: 2032-06-15Common Stock (44,000 underlying)
Footnotes (4)
  • [F1]The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
  • [F2]The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date.
  • [F3]The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
  • [F4]Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date.

Documents

1 file
  • 4
    form4-06172022_010605.xmlPrimary